MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Eli Lilly and Company Long Term Debt Current 2011-2026 | LLY
Annual Long Term Debt Current Eli Lilly and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 222 M | 176 M | 156 M | - | - | - | - | - | - | - | - | - | - | 11.9 M | 1.52 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.52 B | 11.9 M | 417 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
5.82 M | $ 3.44 | -4.32 % | $ 1.03 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K |  USA |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | USA |
 |
ADMA Biologics
ADMA
|
1.1 M | $ 15.36 | -2.17 % | $ 3.66 B | USA |
 |
Cellectis S.A.
CLLS
|
8.38 M | $ 3.53 | -3.54 % | $ 116 M |  France |
 |
AgeX Therapeutics
AGE
|
428 K | - | -10.17 % | $ 12.2 K | USA |
 |
Apellis Pharmaceuticals
APLS
|
7.09 M | $ 20.28 | 0.65 % | $ 2.56 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
23 K | - | -19.68 % | $ 18.4 M | Canada |
 |
AlloVir
ALVR
|
10.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Aptorum Group Limited
APM
|
433 K | $ 0.79 | -1.15 % | $ 4.31 M | China |
 |
Autolus Therapeutics plc
AUTL
|
5.05 M | $ 1.51 | 1.35 % | $ 385 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | USA |
 |
Anika Therapeutics
ANIK
|
1.6 M | $ 14.05 | -1.44 % | $ 206 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
1.8 M | $ 74.36 | -1.64 % | $ 1.44 B | USA |
 |
Applied Therapeutics
APLT
|
429 K | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | USA |
 |
Athersys
ATHX
|
1.01 M | - | 3.77 % | $ 22.4 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
11 K | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
434 K | $ 162.43 | 0.6 % | $ 8.08 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
937 K | $ 8.49 | -0.18 % | $ 1.75 B | USA |
 |
BridgeBio Pharma
BBIO
|
6.19 M | $ 65.66 | -0.78 % | $ 12.6 B | USA |
 |
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
549 K | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellerophon Therapeutics
BLPH
|
203 K | - | -74.18 % | $ 955 K | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
11 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
3.29 M | - | -7.31 % | $ 87 M | USA |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | Canada |
 |
BioLineRx Ltd.
BLRX
|
522 K | $ 2.69 | -0.74 % | $ 908 M |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
8.57 M | $ 61.3 | 1.21 % | $ 11.8 B | USA |
 |
CymaBay Therapeutics
CBAY
|
7 K | - | - | $ 3.45 B | USA |